JP2024545496A5 - - Google Patents

Info

Publication number
JP2024545496A5
JP2024545496A5 JP2024533948A JP2024533948A JP2024545496A5 JP 2024545496 A5 JP2024545496 A5 JP 2024545496A5 JP 2024533948 A JP2024533948 A JP 2024533948A JP 2024533948 A JP2024533948 A JP 2024533948A JP 2024545496 A5 JP2024545496 A5 JP 2024545496A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
dose
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024533948A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024545496A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/052411 external-priority patent/WO2023107697A1/en
Publication of JP2024545496A publication Critical patent/JP2024545496A/ja
Publication of JP2024545496A5 publication Critical patent/JP2024545496A5/ja
Pending legal-status Critical Current

Links

JP2024533948A 2021-12-10 2022-12-09 ヘモグロビンのモジュレーターを投与する方法 Pending JP2024545496A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163288377P 2021-12-10 2021-12-10
US63/288,377 2021-12-10
US202263421524P 2022-11-01 2022-11-01
US63/421,524 2022-11-01
US202263429376P 2022-12-01 2022-12-01
US63/429,376 2022-12-01
PCT/US2022/052411 WO2023107697A1 (en) 2021-12-10 2022-12-09 Methods of administering a modulator of hemoglobin

Publications (2)

Publication Number Publication Date
JP2024545496A JP2024545496A (ja) 2024-12-09
JP2024545496A5 true JP2024545496A5 (cg-RX-API-DMAC7.html) 2025-10-06

Family

ID=85108880

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024533948A Pending JP2024545496A (ja) 2021-12-10 2022-12-09 ヘモグロビンのモジュレーターを投与する方法

Country Status (10)

Country Link
US (1) US20250041312A1 (cg-RX-API-DMAC7.html)
EP (1) EP4444285A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024545496A (cg-RX-API-DMAC7.html)
KR (1) KR20240116826A (cg-RX-API-DMAC7.html)
AU (1) AU2022408097B2 (cg-RX-API-DMAC7.html)
CA (1) CA3241881A1 (cg-RX-API-DMAC7.html)
IL (1) IL312835A (cg-RX-API-DMAC7.html)
MX (1) MX2024007064A (cg-RX-API-DMAC7.html)
TW (1) TW202339732A (cg-RX-API-DMAC7.html)
WO (1) WO2023107697A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023021606A2 (pt) * 2021-05-14 2023-12-19 Global Blood Therapeutics Inc Formas sólidas de modulador de hemoglobina
EP4727555A1 (en) * 2023-06-13 2026-04-22 Global Blood Therapeutics, Inc. (s)-2-hydroxy-6-((4-(2-(2-hydroxyethyl)nicotinoyl)morpholin-3-yl)methoxy)benzaldehyd for use in the treatment of sickle cell disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
PT3880654T (pt) 2018-11-19 2022-04-08 Global Blood Therapeutics Inc Compostos de 2-formil-3-hidroxifeniloximetil capazes de modular hemoglobina
BR112023021606A2 (pt) * 2021-05-14 2023-12-19 Global Blood Therapeutics Inc Formas sólidas de modulador de hemoglobina

Similar Documents

Publication Publication Date Title
JP2023002662A5 (cg-RX-API-DMAC7.html)
TW202202139A (zh) 以2-〔(4-{6-〔(4-氰基-2-氟苄基)氧基〕吡啶-2-基}哌啶-1-基)甲基〕-1-〔(2s)-氧雜環丁烷-2-基甲基〕-1h-苯並咪唑-6-甲酸或其藥學上的鹽治療第2型糖尿病或肥胖症或體重過重
US20240197692A1 (en) Combination Comprising Everolimus and Amcenestrant
JP2018537507A (ja) 加齢に関連する認知障害及び神経炎症を予防及び/又は治療する方法
JP2023535744A5 (cg-RX-API-DMAC7.html)
JP2016518403A (ja) トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療
JP2024531188A5 (cg-RX-API-DMAC7.html)
JP2023548429A5 (cg-RX-API-DMAC7.html)
EP4494701A3 (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
US11413260B2 (en) Use of 1,3-propanedisulfonic acid or pharmaceutically acceptable salts thereof for the treatment of sarcoidosis
JP2023553253A5 (cg-RX-API-DMAC7.html)
US20160287535A1 (en) Uses and Methods for the Treatment of Liver Diseases or Conditions
US11628163B2 (en) 1-piperidinepropionic acid for treating a fibrosing disease
JP2022058873A5 (cg-RX-API-DMAC7.html)
JP6454436B1 (ja) ペマフィブラートを含有する医薬
KR20200014880A (ko) 테세탁셀 및 카페시타빈에 대한 투약 일정
US20140296149A1 (en) Compositions and Methods for the Treatment of Cardiac Surgery-Associated Acute Kidney Injury with Annexin A1 Peptide
JP2021138710A5 (cg-RX-API-DMAC7.html)
WO2024139978A1 (zh) Vofopitant用于治疗肺纤维化的用途
WO2012106947A1 (zh) 含维生素d和二甲双胍的药物组合物
JP2024541770A5 (cg-RX-API-DMAC7.html)
JP6188784B2 (ja) 炎症性および免疫性疾患の治療のための組成物
JP2006519881A5 (cg-RX-API-DMAC7.html)
WO2025080252A1 (en) Methods of use of (4r,5r)-5-(2-chlorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one
TWI672145B (zh) 預防及/或治療代謝疾病的醫藥組合物及其用途